Most cited papers from SocraTec R&D (Germany)

SocraTec R&D (Germany)

What are the most cited papers from SocraTec R&D (Germany)?

The most cited paper from SocraTec R&D (Germany) is "A greener path for the EU Common Agricultural Policy" (Guy Pe’er, Yves M. Zinngrebe, FRANCISCO EDVANDO DE AQUINO MOREIRA et al., 2019), with 508 citations. Next come "Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update" (312) and "Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors" (217).

Published TypeFieldAccessCitations

Showing 50 of 59 papers. Every paper with more than 9 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A greener path for the EU Common Agricultural Policy Guy Pe’er, Yves M. Zinngrebe, FRANCISCO EDVANDO DE AQUINO MOREIRA et al. · Science	Aug 2019	508
2	Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update Ralph‐Steven Wedemeyer, Henning H. Blume · Drug Safety Open access	18 Feb 2014	312
3	Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors Henning H. Blume, Frank Donath, A Warnke et al. · Drug Safety	2006	217
4	Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype Nienwen Chow, Robert D. Bell, Rashid Deane et al. · Proceedings of the National Academy of Sciences Open access	10 Jan 2007	211
5	Exomics and immunogenics Stéphane Champiat, Charles Ferté, Sophie Lebel‐Binay et al. · OncoImmunology Open access	2014	193
6	Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells Zhihui Zhong, Hristelina S. Ilieva, Lee D. Hallagan et al. · Journal of Clinical Investigation Open access	16 Oct 2009	177
7	Pharmaceutical quality of different Ginkgo biloba brands S. Kressmann, Wernér E.G. Müller, Henning H. Blume · Journal of Pharmacy and Pharmacology	May 2002	150
8	The biopharmaceutics classification system (BCS): Class III drugs — better candidates for BA/BE waiver? Henning H. Blume, Barbara S. Schug · European Journal of Pharmaceutical Sciences	Dec 1999	148
9	Magnetic Marker Monitoring: High resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract Werner Weitschies, Henning H. Blume, Hubert Mönnikes · European Journal of Pharmaceutics and Biopharmaceutics	19 Jul 2009	133
10	Formulations of Fentanyl for the Management of Pain Sina Grape, Stephan Alexander Schug, Stefan Lauer et al. · Drugs	28 Dec 2009	109
11	Differential expression level of cytokeratin 8 in cells of the bovine nucleus pulposus complicates the search for specific intervertebral disc cell markers Audrey Gilson, Mathias Dreger, Jill P. G. Urban · Arthritis Research & Therapy Open access	12 Feb 2010	100
12	Dose-proportionality of oral thioctic acid — coincidence of assessments via pooled plasma and individual data Kerstin Breithaupt‐Grögler, Georg Niebch, Edith M. Schneider et al. · European Journal of Pharmaceutical Sciences	Apr 1999	96
13	The influence of hydroxypropyl methylcellulose (HPMC) molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets Arun Kumar Jain, Erik Söderlind, Anna Viridén et al. · Journal of Controlled Release	10 May 2014	86
14	Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union Barbara S. Schug, Erich Brendel, Dörte Wolf et al. · European Journal of Pharmaceutical Sciences	Apr 2002	68
15	The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag‐time after a high fat breakfast Barbara S. Schug, Erich Brendel, E. Chantraine et al. · British Journal of Clinical Pharmacology Open access	Jun 2002	66
16	Analysis of Three-Carrier Ambiguity Resolution Technique for Precise Relative Positioning in GNSS-2 Ulrich Vollath, S. Birnbach, Lukas T. N. Landau et al. · NAVIGATION Journal of the Institute of Navigation	Mar 1999	64
17	Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations S. Kressmann, A. Biber, Meinolf Wonnemann et al. · Journal of Pharmacy and Pharmacology Open access	Nov 2002	62
18	Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: Case example diclofenac Atsushi Kambayashi, Henning H. Blume, Jennifer Dressman · European Journal of Pharmaceutics and Biopharmaceutics	18 Sep 2013	56
19	Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials Kerstin Breithaupt-Groegler, Christoph Coch, Martin Coenen et al. · European Journal of Clinical Pharmacology Open access	7 Jan 2017	54
20	Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast Barbara S. Schug, Erich Brendel, Meinolf Wonnemann et al. · European Journal of Clinical Pharmacology	17 Apr 2002	51
21	Observational study on the tolerability and safety of film-coated tablets containing ivy extract (Prospan® Cough Tablets) in the treatment of colds accompanied by coughing Manuela Stauss‐Grabo, Saynab Atiye, A Warnke et al. · Phytomedicine	6 Jan 2011	49
22	Determination of Hyperforin in Mouse Brain by High-Performance Liquid Chromatography/Tandem Mass Spectrometry Jan-Henning Keller, Michael Karas, Walter E. Müller et al. · Analytical Chemistry	9 Oct 2003	48
23	Bridged bicyclic peptides as potential drug scaffolds: synthesis, structure, protein binding and stability Marco Bartoloni, Xian Jin, María J. Marcaida et al. · Chemical Science Open access	2015	47
24	Felodipine quantification in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry L MIGLIORANCA, Rafael Eliseo Barrientos-Astigarraga, Barbara S. Schug et al. · Journal of Chromatography B	15 Dec 2004	40
25	Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers Xiaoyan Chen, Dafang Zhong, Henning H. Blume · European Journal of Pharmaceutical Sciences	Mar 2000	31
26	Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union Meinolf Wonnemann, Barbara S. Schug, K. Schmücker et al. · International Journal of Clinical Pharmacology and Therapeutics	2006	30
27	Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: Case example diclofenac sodium Atsushi Kambayashi, Henning H. Blume, Jennifer Dressman · European Journal of Pharmaceutics and Biopharmaceutics	23 Jan 2014	30
28	Lack of a pharmacokinetic interaction between steady‐state roflumilast and single‐dose midazolam in healthy subjects Nassr Nassr, Gëzim Lahu, Oliver von Richter et al. · British Journal of Clinical Pharmacology Open access	29 Sep 2006	28
29	How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum Jens Rengelshausen, Kerstin Breithaupt-Groegler, Frank Donath et al. · Therapeutic Innovation & Regulatory Science Open access	3 Feb 2021	27
30	Workshop/Conference Report on EMA Draft Guideline on Validation of Bioanalytical Methods Henning H. Blume, Erich Brendel, Margarete Brudny‐Klöppel et al. · European Journal of Pharmaceutical Sciences	25 Dec 2010	27
31	Comparison of two marketed nifedipine modified-release formulations: An exploratory clinical food interaction study Meinolf Wonnemann, Barbara S. Schug, Maria Anschütz et al. · Clinical Therapeutics	2008	26
32	Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource Drug Products: Workshop summary report Mei‐Ling Chen, Vinod P. Shah, Daan J.A. Crommelin et al. · European Journal of Pharmaceutical Sciences	17 Sep 2011	26
33	Determination of 11-keto-boswellic acid in human plasma Astrid Kaunzinger, Alwin Baumeister, Klaus Cuda et al. · Journal of Pharmaceutical and Biomedical Analysis	May 2002	26
34	The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference Mei‐Ling Chen, Henning H. Blume, Gerald Beuerle et al. · European Journal of Pharmaceutical Sciences	29 Sep 2017	25
35	Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products Rodrigo Cristofoletti, Malcolm Rowland, Lawrence J. Lesko et al. · Journal of Pharmaceutical Sciences	20 Jun 2018	24
36	SAHA Capture Compound – A novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders Jenny J. Fischer, Simon Michaelis, Anna K. Schrey et al. · PROTEOMICS	7 Sep 2011	21
37	Biomarkers and Coagulation Tests for Assessing the Biosimilarity of a Generic Low‐Molecular‐Weight Heparin: Results of a Study in Healthy Subjects With Enoxaparin Karina Kuczka, Sebastian Harder, Bettina Picard‐Willems et al. · The Journal of Clinical Pharmacology	21 Aug 2008	21
38	Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration Maria Anschütz, Meinolf Wonnemann, Barbara S. Schug et al. · International Journal of Clinical Pharmacology and Therapeutics	Feb 2010	20
39	Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products Sven Stegemann, Imre Klebovich, István Antal et al. · European Journal of Pharmaceutical Sciences	25 Sep 2011	20
40	Lidocaine 8 mg Sore Throat Lozenges in the Treatment of Acute Pharyngitis Meinolf Wonnemann, I van der Helm, Manuela Stauss‐Grabo et al. · Arzneimittelforschung	21 Dec 2011	20
41	Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study Michael Böettcher, Gerd Mikus, Dietmar Trenk et al. · Clinical and Translational Science Open access	17 Mar 2022	19
42	Pain relief of sore throat with a new anti-inflammatory throat lozenge, ibuprofen 25 mg: A randomised, double-blind, placebo-controlled, international phase III study Athmane Bouroubi, Yves Donazzolo, Franck Donath et al. · International Journal of Clinical Practice Open access	Sep 2017	18
43	Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study Michael Böettcher, Hans‐Dirk Düngen, Frank Donath et al. · Clinical Pharmacology & Therapeutics Open access	8 Mar 2022	17
44	Development of a furosemide-containing expandable system for gastric retention Marco Neumann, Claudia Heimhardt, Knut Seidlitz et al. · Journal of Controlled Release	18 Aug 2021	16
45	Investigation of the Dissolution Characteristics of Nifedipine Extended-Release Formulations Using USP Apparatus 2 and a Novel Dissolution Apparatus Grzegorz Garbacz, Henning H. Blume, Werner Weitschies · Dissolution Technologies Open access	2009	16
46	Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography–tandem mass spectrometry Xiaoyan Chen, Dafang Zhong, Haiyan Xu et al. · Journal of Chromatography B Biomedical Sciences and Applications	May 2001	16
47	Sensitive and specific liquid chromatographic–tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma Xiaoyan Chen, Dafang Zhong, Haiyan Xu et al. · Journal of Chromatography B	Mar 2002	15
48	Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes M. Böttcher, Hans‐Dirk Düngen, Vasile Corcea et al. · American Journal of Cardiovascular Drugs Open access	12 Jan 2023	14
49	Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers Torsten Zimmermann, Joachim Höchel, Michael Becka et al. · British Journal of Clinical Pharmacology Open access	10 Jan 2018	14
50	Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial Björn Schurad, Cornelius Koch, Barbara S. Schug et al. · Current Alzheimer Research Open access	Jun 2022	13

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.